These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 29575209)

  • 1. Rapid Oligonucleotide Drug Impurity Determination by Direct Spectral Comparison of Ion Pair-Reversed Phase HPLC ESI MS Data.
    Roussis SG; Koch C; Capaldi D; Rentel C
    Rapid Commun Mass Spectrom; 2018 Mar; ():. PubMed ID: 29575209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semi-quantitative determination of co-eluting impurities in oligonucleotide drugs using ion-pair reversed-phase liquid chromatography mass spectrometry.
    Roussis SG; Cedillo I; Rentel C
    J Chromatogr A; 2019 Jan; 1584():106-114. PubMed ID: 30473112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated determination of early eluting oligonucleotide impurities using ion-pair reversed-phase liquid chromatography high resolution-mass spectrometry.
    Roussis SG; Cedillo I; Rentel C
    Anal Biochem; 2020 Apr; 595():113623. PubMed ID: 32067983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of individual oligonucleotide impurities by small amine ion pair-RP HPLC MS and MS/MS: n - 1 impurities.
    Roussis SG; Rodriguez AA; Rentel C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Apr; 1169():122611. PubMed ID: 33706187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities--part II.
    Háda V; Dubrovay Z; Lakó-Futó A; Galambos J; Gulyás Z; Aranyi A; Szántay C
    J Pharm Biomed Anal; 2013 Oct; 84():309-22. PubMed ID: 23177164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impurity Qualification Toxicology Study for a 2'-O-Methoxyethyl-Modified Antisense Inhibitor in Mice.
    Kim TW; Papagiannis C; Capaldi D; McPherson AK; Mahdi F; Luu N; Rodriguez AA; Hoffmaster C; Serota D; Henry SP
    Nucleic Acid Ther; 2020 Feb; 30(1):14-21. PubMed ID: 31687889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Separation and identification of impurities from intermediates of istradefylline].
    Wang Y; Lü X; Xu H; Meng Z; Li J; Xu Z; Xue M
    Se Pu; 2021 Apr; 39(4):430-436. PubMed ID: 34227764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active drug substance impurity profiling part II. LC/MS/MS fingerprinting.
    Nicolas EC; Scholz TH
    J Pharm Biomed Anal; 1998 Jan; 16(5):825-36. PubMed ID: 9535195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An integrated approach for detection and characterization of the trace impurities in levofloxacin using liquid chromatography-tandem mass spectrometry.
    Zheng YJ; He JM; Zhang RP; Wang YC; Wang JX; Wang HQ; Wu Y; He WY; Abliz Z
    Rapid Commun Mass Spectrom; 2014 May; 28(10):1164-74. PubMed ID: 24711279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of impurities in semi-synthetic vinorelbine bitartrate by HPLC-MS with mass spectrometric shift technique.
    Cao X; Tai Y; Sun C; Wang K; Pan Y
    J Pharm Biomed Anal; 2005 Sep; 39(1-2):39-45. PubMed ID: 16085133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impurity profiling of Compound Amino Acid Injection (6AA) using ion-pair high performance liquid chromatography coupled with corona-charged aerosol detection and high resolution mass spectrometry.
    Qiu X; Zuo L; Sun S; Zhao X; Xu S; Zhu Z; Zhao T; Sun Z; Yao J; Shan G
    J Pharm Biomed Anal; 2021 Jul; 201():114099. PubMed ID: 33957362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impurity profiling of anticancer preclinical candidate, IIIM-290.
    Kumar V; Bhurta D; Sharma A; Kumar P; Bharate SB; Vishwakarma RA; Bharate SS
    J Pharm Biomed Anal; 2019 Mar; 166():1-5. PubMed ID: 30590350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the use of the desirability function to optimize the separation of oligonucleotide impurities by ion pair-RP LCMS.
    Roussis SG; Rentel C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Apr; 1220():123666. PubMed ID: 36921438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the Stress Testing Characteristics of Apixaban, Structural Elucidation of a Novel Degradation Impurity, and Stability-Indicating Method Development for Quantification of Related Substances.
    Surukonti SR; Surendrababu MS
    J AOAC Int; 2024 Jan; 107(1):22-30. PubMed ID: 37698982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Five Oxidative Degradation Impurities and One Process Impurity of Suvorexant Drug Substance by LC-MS/MS, HR-MS and 1D, 2D NMR: Validation of Suvorexant Drug Substance and Process Impurities by HPLC and UPLC.
    Rajana N; Devi DR; Kumar Reddy DN; Babu JM; Basavaiah K; Balakumaran K
    J Chromatogr Sci; 2020 Apr; 58(5):433-444. PubMed ID: 32134104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the impurity profile and polymerized impurity in mezlocillin sodium by multiple heart-cutting two-dimensional liquid chromatography coupled with ion trap time-of-flight mass spectrometry.
    Wang J; Zhou J; Xu Y; Zhu B; Li H
    Rapid Commun Mass Spectrom; 2019 Sep; 33(17):1410-1419. PubMed ID: 31148276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assay, Purity, and Impurity Profile of Phosphorothioate Oligonucleotide Therapeutics by Ion Pair-HPLC-MS.
    Rentel C; Gaus H; Bradley K; Luu N; Kolkey K; Mai B; Madsen M; Pearce M; Bock B; Capaldi D
    Nucleic Acid Ther; 2022 Jun; 32(3):206-220. PubMed ID: 35238617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of RP UPLC-TOF/MS, stability indicating method for omeprazole and its related substances by applying two level factorial design; and identification and synthesis of non-pharmacopoeial impurities.
    Jadhav SB; Kumar CK; Bandichhor R; Bhosale PN
    J Pharm Biomed Anal; 2016 Jan; 118():370-379. PubMed ID: 26600119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality by design with design of experiments approach for development of a stability-indicating LC method for enzalutamide and its impurities in soft gel dosage formulation.
    Katakam LNR; Dongala T; Ettaboina SK
    Biomed Chromatogr; 2021 May; 35(5):e5062. PubMed ID: 33410554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenofibrate raw materials: HPLC methods for assay and purity and an NMR method for purity.
    Lacroix PM; Dawson BA; Sears RW; Black DB; Cyr TD; Ethier JC
    J Pharm Biomed Anal; 1998 Nov; 18(3):383-402. PubMed ID: 10096833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.